RU58841 is used for hair loss, with some users reporting decreased shedding and preserved hairlines. Concerns about safety and side effects like heart issues are noted, and some combine it with finasteride and minoxidil for better results.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
A 32-year-old male with hair loss cannot use finasteride due to erectile dysfunction and minoxidil due to scalp psoriasis. He seeks alternative treatments for his condition.
A 44-year-old user experienced hair regrowth using a topical spray combining 0.3% finasteride and 7% minoxidil after switching from oral finasteride due to side effects. The user reported noticeable improvements in hair thickness after four months without any side effects from the topical treatment.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
The user humorously describes trying various hair loss treatments, including minoxidil, finasteride, and RU58841, with a satirical twist involving psychedelic experiences and imaginary entities. They mistakenly used LSD instead of RU58841 and plan to continue experimenting with other substances.
A Danish citizen warns against NordicHairGrowth.com, claiming it falsely advertises products for treating androgenic alopecia. The company's ingredients and claims are disputed, including a non-existent patented ingredient RP-24, and a non-verifiable clinical trial.
The user has been using oral minoxidil, dutasteride, and RU58841 but continues to experience hair loss. They seek advice on why the treatments aren't working and if others have had similar experiences.
RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.
A 23-year-old male shares his 4-month hair regrowth progress using oral minoxidil, oral finasteride, collagen, biotin, keto shampoo, and dermarolling. He notices fuller hair but minimal visible change, and considers adding topical minoxidil despite concerns about consistency.
The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.
A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.
User shares 4-month hairline progress using minoxidil, finasteride, nizoral, and dermarolling. Others discuss treatment details and express admiration for the results.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
RU58841 for hair loss, discussing sources, application methods, and carriers like PG + ethanol or liquid minoxidil. Users share experiences with premixed solutions and powder forms, noting price differences and storage importance.
Reishi mushroom is significantly weaker than finasteride for inhibiting 5 alpha reductase, requiring much larger quantities to achieve similar effects. The effectiveness and safety of consuming large amounts of Reishi for hair loss are uncertain.
User shared positive results after 4 months using 1.25mg finasteride, topical minoxidil, daily biotin, and weekly dermarolling. They expressed gratitude to another user for the advice.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.